Egr-1 expression. In summary, these results suggest that PKA-mediated suppression of Ang-II-induced Egr-1 expression and phosphorylation of ERK may be among the mechanisms by which cAMP exerts its vasculoprotective effects.
are believed to contribute to abnormal vascular function leading to the pathogenesis of vascular diseases (Rivard and Andres 2000) . These events are promoted by elevated concentrations of vasoactive peptides such as angiotensin-II (Ang-II) which plays an important role in vascular function (Montezano et al. 2014; Nakashima et al. 2006) . At the cellular level, exaggerated stimulation by Ang-II results in a phenotypic switch of VSMC that progressively differentiate from a contractile state to a synthetic state (Campbell and Campbell 1985) . Synthetic VSMC are characterized by hyperproliferative properties and enhanced migratory capacities (Potier et al. 2009 ). These features induce pathological neointima formation and subsequent vessel narrowing. At the signaling level, elevated levels of Ang-II mediate the hyperactivation of growth promoting signaling pathways involving the mitogen-activated protein kinase (MAPK)-mediated cascade and related transcriptional events (Touyz and Berry 2002 ) that contribute to the regulation of genes implicated in vascular remodeling (Cipolletta et al. 2010; Duff et al. 1995; Hartney et al. 2011 ).
Enhanced levels of 3'-5'-cyclic adenosine monophosphate (cAMP) produced via adenylate cyclase (AC) activity have been reported to antagonize vasoactive peptide-and mitogen-induced proliferative responses in VSMC (Begum et al. 2011; Graves et al. 1993; Hewer et al. 2011 ). One of the major effector involved in transducing cAMPinduced events is protein kinase A (PKA). The β-agonist isoproterenol (ISO), known to increase cAMP via G-protein-coupled receptor (GPCR)-mediated AC activation, has been demonstrated to inhibit Ang-II-induced VSMC proliferation (Kim et al. 2009 ). In D r a f t accordance with this, functional abnormalities in the coupling of β-adrenergic receptor agonism are associated with alterations in the signaling events regulating VSMC proliferation (Gros et al. 2006) . Impairments in cAMP-induced signaling have also been correlated with a rise in blood pressure and related dysfunctional features in VSMC (Shahid et al. 2010 ).
An involvement of the early growth response protein-1 (Egr-1), a zinc finger containing transcription factor, in the pathogenesis of vascular diseases has recently been demonstrated in experimental models of atherosclerosis and vascular injury (Khachigian 2006; Ohtani et al. 2004; Santiago et al. 1999; Vazquez-Padron et al. 2010) . The presence of Egr-1 binding motifs within the structure of several pro-atherogenic genes has suggested that Egr-1 modulates vascular physiology in response to several stimuli (McCaffrey et al. 2000) . Growth-promoting stimuli and several vasoactive peptides have been demonstrated to enhance Egr-1 expression and activity in VSMC and other vascular cells (Bouallegue et al. 2013; Iyoda et al. 2012; Liu et al. 2013; Youreva et al. 2013; Youreva and Srivastava 2016) . With regard to the molecular mechanisms underlying Egr-1 expression, we recently demonstrated that Ang-II upregulates Egr-1 levels in VSMC via a pathway that involves calcium signaling components upstream of ERK 1/2 -mediated molecular events (Simo-Cheyou et al. 2017 ) .
Previous studies showing that deletion of Egr-1 suppresses the vasculoprotective effects of cAMP elevating agents in VSMC have suggested a link between cAMPdependent signaling and Egr-1 expression and activity (Kimura et al. 2014 
Materials and methods

Antibodies and reagents
Ang-II (#A9525), forskolin (#F6886), dibutyryl-cAMP (#D0260), were purchased from Sigma-Aldrich (St. Louis, MO, USA). N6-Benzoyl-adenosine 3', 5'-cyclic monophosphate sodium salt (BNZ) (#116802) was purchased from EMD Millipore (Etobicoke, ON, Canada). Phosphorylated ERK 1/2 (#SC16982-R) antibody was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Egr-1 (#4153S), total (#3112S) and Ser157 phosphorylated VASP (#3111S), β-tubulin (#2146S), and anti-rabbit (#7074S)
antibodies were purchased from Cell Signaling Technology (Beverly, Massachusetts, USA). The enhanced chemiluminescence (ECL) detection system kit was purchased from
Perkin Elmer (Montreal, QC, Canada).
Cell culture
VSMC derived from the medial layer of rat thoracic aortae (A-10 cell line (CRL-1476) from ATCC, Manassas, USA) were maintained in culture with Dulbecco's modified eagle medium (DMEM) containing 10% fetal bovine serum (FBS) and 1%
penicillin/streptomycin at 37ºC in a humidified atmosphere of 5% CO 2, as described earlier (Bouallegue et al. 2007) . Cells between passages 4 and 8 were grown to 80-90% confluence in 60-mm dishes and incubated in serum and antibiotic-free DMEM 5 hours prior to treatments.
Cell lysis and immunoblotting
Quiescent A-10 VSMC were incubated in the absence or presence of various reagents for 30 minutes followed by stimulation with 100 nM Ang-II for indicated time periods. The cells were washed three times with ice-cold PBS and lysed in 100 µL radio- Figure 3A , heightened levels of Egr-1 observed in response to Ang-II were attenuated by pre-treatment with IBMX suggesting that increase in cAMP levels by PDE inhibition can also attenuate Ang-II-induced signaling leading to Egr-1 expression ( Fig.3A) . Moreover, simultaneous addition of IBMX along with ISO resulted in a further decrease in Ang-II-induced Egr-1 expression (Fig.3B) . Together, these data demonstrated that cAMP plays a key role in ISO-mediated inhibition of Ang-II-induced
Egr-1 expression. In addition, since the phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) has been used as a marker of cAMP signaling and protein kinase A activation (Butt et al. 1994; Eckert and Jones 2007; Harbeck et al. 2000; Joshi et al. 2011) , it was of interest to examine the patterns of VASP phosphorylation associated with reduced Egr-1 levels. We therefore used an antibody able to detect both the 46 kDa total VASP protein and VASP phosphorylated at serine 157 exhibiting a shift at 50kDa due to phosphorylation-induced altered electrophoretic mobility (Butt et al. 1994; Harbeck et al. 2000) . Figure 4A and B show that IBMX does not trigger a detectable increase in phosphorylation of VASP as compared to the unstimulated cells ( Fig.4A and   4B ). However, IBMX-mediated attenuation of Ang-II-induced Egr-1 expression is accompanied with an induction of VASP phosphorylation as measured by the ratio of serine 157 phosphorylated VASP over the total protein (Fig.4A) . Furthermore, similar to the additive effect produced towards Egr-1 downregulation, simultaneous treatment with ISO and IBMX resulted in a more robust increase in Ser157 phosphorylation of VASP as compared with individual treatment with either ISO or IBMX (Fig.4B) . Taken together, these data demonstrate that sustained elevation of cAMP results in a more potent VASP phosphorylation that correlates with a potentiation of isoproterenol-mediated inhibitory effect on Ang-II-induced Egr-1 expression.
PKA signaling exerts an inhibitory effect on Ang-II-induced Egr-1 expression
Because increased VASP phosphorylation on serine 157 corresponds to an enhanced PKA activity in several types of cells and since PKA activity interferes with proliferative responses in VSMC (Hewer et al. 2011) , we next sought to assess the role of PKA in the attenuation of Ang-II-induced Egr-1 expression. For this purpose, we D r a f t examined the effects of the cell permeable analog of cAMP, dibutyryl cAMP (Db-cAMP) and a cAMP analog that specifically activates PKA in the cells, benzoyl-cAMP (BNZcAMP). As depicted in Figure 5 , similar to ISO and FSK, both Db-cAMP and BNZcAMP attenuated Ang-II-induced Egr-1 expression in a dose-dependent fashion (Fig.5A) suggesting the contribution of PKA in downregulating Ang-II-induced Egr-1 expression (Fig.5B) . increasing cAMP by inhibiting PDE activity in VSMC exerts a similar effect. A large body of evidence has indicated that cAMP exerts a growth inhibitory effect in VSMC and reduces neointima formation in vascular injury (Gusan and Anand-Srivastava 2013; Indolfi et al. 1997; Kim et al. 2009; Lehrke et al. 2015; Palmer et al. 1998; Takahashi et al. 1996) . In view of the reported involvement of Egr-1 in neointima formation in vesselinjured models (Lowe et al. 2001; Wang et al. 2013 Although an attenuating effect of cAMP in serum-induced Egr-1 expression in VSMC has been reported earlier (Hewer et al. 2011) , the present studies have demonstrated for the first time that cAMP signaling via PKA is able to block Ang-II-induced Egr-1 expression in VSMC.
We have shown earlier that ERK1/2 activation is critical to induce protein and The control is defined as 1 and each value aside is expressed as fold increase compared to the control value defined as 1. 
